2013
Jordheim LP, Marton Z, Rhimi M,
Cros-Perrial E, Lionne C, Peyrottes C,
Dumontet C, Aghajari N & Chaloin L. Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening. Biohemical Pharmacol, 2013, 85, (4): 497-506.
2012
Marechal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Andre T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Deviere J, Emile JF & Van Laethem JL. Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma. Gastroenterology, 2012, 143, (3): 664-674.
Callens C, Baleydier F, Lengline E, Ben Abdelali R, Petit A, Villarese P, Cieslak A, Minard-Colin V, Rullier A, Moreau A, Baruchel A, Schmitt C, Asnafi V, Bertrand Y & Macintyre E. Clinical Impact of NOTCH1 and/or FBXW7 Mutations, FLASH Deletion, and TCR Status in Pediatric T-Cell Lymphoblastic Lymphoma. J Clin Oncol, 2012, 30, (16): 1966-1973.
Lapusan S, Vidriales MB,
Thomas X, de Botton S, Vekhoff A, Tang R,
Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, Deangelo DJ, Giles FJ & Marie JP. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs, 2012, 30, (3): 1121-1131.
Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP & Seve P. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol, 2012, 23, (1): 86-93.
2011
Baleydier F, Domenech C & Thomas X. Novel conventional therapies in onco-hemathology. Bull Cancer, 2011, 98, (8): 901-913.
Dalle S, Poulalhon N & Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011a, 365, (15): 1448-1449; author reply 1450.
Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, Friess T, Umana P, Klein C & Dumontet C. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther, 2011, 10 (1): 178-185.
Gallier F, Lallemand P, Meurillon M, Jordheim LP, Dumontet C, Perigaud C, Lionne C, Peyrottes S & Chaloin L. Structural Insights into the Inhibition of Cytosolic 5'-Nucleotidase II (cN-II) by Ribonucleoside 5'-Monophosphate Analogues. PLoS Comput Biol, 2011, 7 (12): e1002295.
Jordheim LP, Seve P, Tredan O & Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol, 2011, 12 (7): 693-702.
Tagoug I, Sauty De Chalon A & Dumontet C. Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. PLoS One, 2011, 6 (7): e22641.
Cliquez ici pour voir une liste complète des publications des membres de l'équipe Anticorps-Anticancer du 1er janvier 2011 au 29 mars 2013.